Advertisement
Roivant Sciences Ltd. (ROIV)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
| Previous Close | 11.82 |
| Open | 11.83 |
| Bid | 12.49 x 400 |
| Ask | 12.54 x 300 |
| Day's Range | 11.78 - 12.57 |
| 52 Week Range | 8.61 - 13.06 |
| Volume | |
| Avg. Volume | 6,203,771 |
| Market Cap | 9.121B |
| Beta (5Y Monthly) | 1.24 |
| PE Ratio (TTM) | 2.26 |
| EPS (TTM) | 5.54 |
| Earnings Date | Feb 11, 2025 - Feb 17, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.21 |
Simply Wall St.Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution
The latest earnings release from Roivant Sciences Ltd. ( NASDAQ:ROIV ) disappointed investors. We did some analysis and...
GlobeNewswireRoivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2024, and provided a business update. Brepocitinib 52-week data from the Phase 2 NEPTUNE study in non-infectious uveitis (NIU) showed potential best-in-indication efficacy sustained to one year; first patients enrolled in Phase 3 NIU program IMVT-1402 cleared five Investigational New Drug (IND) applications across a r
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.